Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elanco Animal HealthELAN +1.74%68 EV-to-EBIT is 187.37 as of Aug. 23, 2026, which is 1234% above its 10-year median of 14.05. GuruFocus rates ELAN with a GF Score™ of 68/100 and a GF Value™ of $16.66 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 694 Drug Manufacturers companies, Elanco Animal Health ranks worse than 97.26% on this metric.
Elanco Animal Health (NYSE:ELAN) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Elanco Animal Health's Enterprise Value for the quarter that ended in Jun. 2026 was $15,682 Mil.
Elanco Animal Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elanco Animal Health EV-to-EBIT Related Terms
Elanco Animal Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Elanco Animal Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elanco Animal Health EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Elanco Animal Health's EV-to-EBIT falls into.
Elanco Animal Health's current Enterprise Value is $15,364 Mil.
Elanco Animal Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elanco Animal Health (ELAN) has a EV-to-EBIT of 187.37 as of Aug. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Elanco Animal Health and its competitors. This is 1234% above median its historical median of 14.05. According to the industry distribution chart, Elanco Animal Health ranks #675 out of 694 companies in the Drug Manufacturers industry, placing it in the top 97.3%.
Is Elanco Animal Health's EV-to-EBIT too high?
Elanco Animal Health's current EV-to-EBIT of 187.37 is 1234% above median its 10-year median of 14.05. The Drug Manufacturers industry median EV-to-EBIT is 15.70. Elanco Animal Health's value of 187.37 is 1093.8% above this industry median. Based on the distribution chart, Elanco Animal Health ranks #675 out of 694 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Elanco Animal Health has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Elanco Animal Health's EV-to-EBIT compare to ALKS and LQDA?
According to the Drug Manufacturers industry distribution chart, Elanco Animal Health ranks #675 out of 694 companies for EV-to-EBIT. This places Elanco Animal Health in the lower half of its industry. The industry median EV-to-EBIT is 15.70. Elanco Animal Health's value of 187.37 is 1093.8% above this benchmark. While the company's 10-year median is 14.05 vs. the industry median of 15.70, Elanco Animal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.70, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elanco Animal Health's current EV-to-EBIT of 187.37 is 1093.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Elanco Animal Health and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elanco Animal Health's current EV-to-EBIT is 187.37, which is 1234% above median its own 10-year median of 14.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elanco Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Elanco Animal Health (ELAN) is currently considered Significantly Overvalued. The stock's GF Value™ is $16.66, compared to a current price of $23.97 — trading 43.9% above its estimated fair value. The current EV-to-EBIT is 187.37, which is 1234% above median its 10-year median of 14.05 and 1093.8% above the Drug Manufacturers industry median of 15.70. Elanco Animal Health's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Elanco Animal Health (ELAN), the current EV-to-EBIT is 187.37 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elanco Animal Health (ELAN) Overvalued in 2026?
Based on GuruFocus' analysis, Elanco Animal Health stock appears to be overvalued.
The current stock price of $23.97 is trading 43.9% above its estimated GF Value™ of $16.66.
GuruFocus considers Elanco Animal Health to be Significantly Overvalued.
Key valuation signals for ELAN:
EV-to-EBIT: 187.37 (1234% above median its 10-year median of 14.05)
GF Value™: $16.66 vs. price of $23.97 (43.9% above fair value)
Industry Position: 1093.8% above the Drug Manufacturers median (#675 of 694)
No single metric tells the full story. See the ELAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
68GF Score
Get the complete analysis for ELAN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELAN has been successfully added to your 
